#1
#1 out of 1100.00%
health3h ago
Key facts: FDA Approves Baxfendy; Citi Keeps 18,000p on AstraZeneca
- FDA approves Baxfendy for adults with high blood pressure not controlled by two drugs.
- AstraZeneca bought Baxfendy from CinCor in 2023; Phase III results were positive.
- Citi maintains an 18,000p target on AstraZeneca amid recent stock moves.
- Upcoming Phase III readouts may act as near-term catalysts for AstraZeneca.
- TradingView reports provide a concise overview of Baxfendy’s approval and AZN outlook.
- AstraZeneca’s Baxfendy history traces to its 2023 Baxfendy acquisition from CinCor.
- The article notes Baxfendy’s Phase III results were positive.
- AZN stock activity described as down about 10% last month.
- The report emphasizes Revenue potential exceeding $5 billion from Baxfendy.
Vote 0